Belimumab Efficacy is `Mild' but Market Potential Still Great†: Anticipating US Approval of the First Lupus Drug Since 1957

Author： Weintraub Ben  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.3, 2011-06, pp. : 203-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus

By Scott Lesley J.   Burness Celeste B.   McCormack Paul L.  

BioDrugs, Vol. 26, Iss. 3, 2012-06 ,pp. : 195-199

Adis International

Access to resources Recommend Favorite

Regulatory Aspects of Post-Approval Safety Reporting for Generic Drug Products in the US

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 3, Iss. 3, 2016-12 ,pp. : 142-150

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Treatment of Cutaneous Lupus

By Reid C.  

American Journal of Clinical Dermatology, Vol. 1, Iss. 6, 2000-11 ,pp. : 375-379

Adis International

Access to resources Recommend Favorite

The US Approach to Biosimilars: The Long-Awaited FDA Approval Pathway

By Calvo Begoña   Zuñiga Leyre  

BioDrugs, Vol. 26, Iss. 6, 2012-12 ,pp. : 357-361

Adis International

Access to resources Recommend Favorite

Subjective Outcome Measures of Drug Efficacy

By Courcier-Duplantier Soizic  

Therapie, Vol. 58, Iss. 3, 2003-01 ,pp. : 267-273

Adis International

Access to resources Recommend Favorite